Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation.
Carter
W Grady
WG
Shillcutt
Samuel D
SD
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D003511:Cyclohexanols / Q000627:therapeutic use*; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000188:drug therapy / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D016728:Self-Injurious Behavior / Q000188:drug therapy* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012867:Skin / Q000293:injuries*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D014150:Antipsychotic Agents; D000068180:Aripiprazole; D003511:Cyclohexanols; D010879:Piperazines; D015363:Quinolones; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride